<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1867">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01659736</url>
  </required_header>
  <id_info>
    <org_study_id>DIEF003523.1</org_study_id>
    <nct_id>NCT01659736</nct_id>
  </id_info>
  <brief_title>Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder</brief_title>
  <official_title>Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Neuronetics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hartford Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is investigating a new indication of Transcranial Magnetic Stimulation (TMS) by
      conducting a pilot randomized-controlled trial (RCT) comparing structural
      neuronavigation-directed TMS to Sham-TMS Placebo therapy for treatment of Generalized
      Anxiety Disorder (GAD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty participants (n = 10 per group) will be recruited. Participants will complete
      structural MRI for neuronavigation. Participants will be randomly assigned to treatment
      condition. TMS or Sham-TMS sessions will occur daily 5 days/week for 6 weeks. Assessments
      will occur at pretreatment, weekly during treatment, post-treatment, and 3 month.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in the Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) at Post-treatment and 3-month Follow-up.</measure>
    <time_frame>Pretreatment, Post-treatment, 3-month follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder Status</measure>
    <time_frame>Post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety. Responder status was defined as a ≥ 50% improvement (i.e., reduction) in SIGH-A scores from pre-treatment to post-treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission Status</measure>
    <time_frame>post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety. Remission status was defined as a SIGH-A score &lt; 8 and Clinical Global Impression Improvement score = 1 (&quot;very much improved&quot;) or 2 (&quot;much improved&quot;) at post-treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder Status</measure>
    <time_frame>3-month follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety. Responder status was defined as a ≥ 50% improvement (i.e., reduction) in SIGH-A scores from pre-treatment to 3-month follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission Status</measure>
    <time_frame>3-month follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety. Remission status was defined as a SIGH-A score &lt; 8 and Clinical Global Impression Improvement score = 1 (&quot;very much improved&quot;) or 2 (&quot;much improved&quot;) at 3-month follow-up.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>TMS Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMS treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMS-Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This is a sham TMS condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS</intervention_name>
    <description>Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.</description>
    <arm_group_label>TMS Therapy</arm_group_label>
    <arm_group_label>TMS-Sham</arm_group_label>
    <other_name>Transcranial Magnetic Stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with GAD as the principal or co-principal disorder

          -  Clinical Global Impression Score ≥ 4

          -  Hamilton Anxiety Rating Scale ≥ 18

          -  Hamilton Rating Scale for Depression ≤ 17

          -  Fluency in English

          -  Capacity to understand the nature of the study and willingness to sign informed
             consent form.

        Exclusion Criteria:

          -  History of epilepsy or head trauma (LOC &gt; 5 minutes) within the past 6 months.

          -  Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain
             tumor, multiple sclerosis, or brain surgery.

          -  A review of patient medications by the study physician indicates an increased risk of
             seizure.

          -  An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any
             unstable cardiac disease; hypertension; or severe renal or liver insufficiency.

          -  Substance use disorder or PTSD within the past 6 months.

          -  Lifetime bipolar disorder, obsessive-compulsive disorder (OCD), psychotic disorder,
             mental retardation, or pervasive developmental disorder.

          -  Any psychotic features, including dementia or delirium. Concurrent psychotherapy and
             unwillingness to discontinue

          -  Medication change within past 3 months.

          -  Current serious suicidal or homicidal ideation, and/or serious suicidal attempt
             within past 6 months.

          -  Serious, unstable, or terminal medical condition or clinically judged too
             psychiatrically unstable to participate in the study.

          -  Any contraindication for participation in MRI scan
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gretchen J Diefenbach, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartford Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 2, 2015</lastchanged_date>
  <firstreceived_date>May 25, 2012</firstreceived_date>
  <firstreceived_results_date>April 8, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TMS-Treatment</title>
          <description>TMS treatment
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
        </group>
        <group group_id="P2">
          <title>TMS-Sham</title>
          <description>This is a sham TMS condition
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Post-Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9">n = 10, but data from one completer was excluded from all analyses due to protocol violation.</participants>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>3-month Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TMS Therapy</title>
          <description>TMS treatment
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
        </group>
        <group group_id="B2">
          <title>TMS-Sham</title>
          <description>This is a sham TMS condition
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="44.00" spread="11.95"/>
                <measurement group_id="B2" value="44.58" spread="14.75"/>
                <measurement group_id="B3" value="44.28" spread="13.09"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) at Post-treatment and 3-month Follow-up.</title>
        <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety.</description>
        <time_frame>Pretreatment, Post-treatment, 3-month follow-up</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat sample (n = 25)</population>
        <group_list>
          <group group_id="O1">
            <title>TMS-Treatment</title>
            <description>TMS treatment
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMS-Sham</title>
            <description>This is a sham TMS condition
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in the Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) at Post-treatment and 3-month Follow-up.</title>
            <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>pre-treatment</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.31" spread="5.23"/>
                  <measurement group_id="O2" value="20.75" spread="3.72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>post-treatment</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.10" spread="5.77"/>
                  <measurement group_id="O2" value="14.38" spread="4.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3-month follow-up</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.36" spread="7.86"/>
                  <measurement group_id="O2" value="17.95" spread="7.48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.006</p_value>
            <p_value_desc>p-value is for the condition (active TMS versus Sham) by time (pre, post, 3-month follow-up) interaction</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Responder Status</title>
        <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety. Responder status was defined as a ≥ 50% improvement (i.e., reduction) in SIGH-A scores from pre-treatment to post-treatment.</description>
        <time_frame>Post-treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>Post-treatment completers</population>
        <group_list>
          <group group_id="O1">
            <title>TMS- Treatment</title>
            <description>TMS treatment
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMS- Sham</title>
            <description>This is a sham TMS condition
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Responder Status</title>
            <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety. Responder status was defined as a ≥ 50% improvement (i.e., reduction) in SIGH-A scores from pre-treatment to post-treatment.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Remission Status</title>
        <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety. Remission status was defined as a SIGH-A score &lt; 8 and Clinical Global Impression Improvement score = 1 (&quot;very much improved&quot;) or 2 (&quot;much improved&quot;) at post-treatment.</description>
        <time_frame>post-treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>Post-treatment completers</population>
        <group_list>
          <group group_id="O1">
            <title>TMS-Treatment</title>
            <description>TMS treatment
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMS-Sham</title>
            <description>This is a sham TMS condition
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Remission Status</title>
            <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety. Remission status was defined as a SIGH-A score &lt; 8 and Clinical Global Impression Improvement score = 1 (&quot;very much improved&quot;) or 2 (&quot;much improved&quot;) at post-treatment.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Responder Status</title>
        <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety. Responder status was defined as a ≥ 50% improvement (i.e., reduction) in SIGH-A scores from pre-treatment to 3-month follow-up.</description>
        <time_frame>3-month follow-up</time_frame>
        <safety_issue>No</safety_issue>
        <population>3-month follow-up completers</population>
        <group_list>
          <group group_id="O1">
            <title>TMS-Treatment</title>
            <description>TMS treatment
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMS-Sham</title>
            <description>This is a sham TMS condition
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Responder Status</title>
            <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety. Responder status was defined as a ≥ 50% improvement (i.e., reduction) in SIGH-A scores from pre-treatment to 3-month follow-up.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Remission Status</title>
        <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety. Remission status was defined as a SIGH-A score &lt; 8 and Clinical Global Impression Improvement score = 1 (&quot;very much improved&quot;) or 2 (&quot;much improved&quot;) at 3-month follow-up.</description>
        <time_frame>3-month follow-up</time_frame>
        <safety_issue>No</safety_issue>
        <population>3-month follow-up completers</population>
        <group_list>
          <group group_id="O1">
            <title>TMS-Treatment</title>
            <description>TMS treatment
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMS-Sham</title>
            <description>This is a sham TMS condition
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Remission Status</title>
            <description>Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) scores range from 0-56 with higher scores indicating more severe anxiety. Remission status was defined as a SIGH-A score &lt; 8 and Clinical Global Impression Improvement score = 1 (&quot;very much improved&quot;) or 2 (&quot;much improved&quot;) at 3-month follow-up.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TMS-Treatment</title>
          <description>TMS treatment
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
        </group>
        <group group_id="E2">
          <title>TMS-Sham</title>
          <description>This is a sham TMS condition
TMS: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Treatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>A patient in the active group was hospitalized for evaluation of chest pain; however, the event was determined to be unrelated to the study intervention.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pin Prick Sensation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain at the stimulation site</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Facial pain (including eye pain)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lightheaded or Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Facial twitch</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gretchen J. Diefenbach, Ph.D</name_or_title>
      <organization>The Institute of Living</organization>
      <phone>860-545-7685</phone>
      <email>Gretchen.Diefenbach@hhchealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
